Literature DB >> 3750844

Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA.

D D Auperin, D R Sasso, J B McCormick.   

Abstract

Two overlapping cDNA clones corresponding to the 5' region of the Lassa virus S genome RNA were isolated and their nucleotide sequences determined. Similar to Pichinde and lymphocytic choriomeningitis viruses (LCMV), Lassa virus has an ambisense S RNA. The precursor to the viral glycoproteins (GPC) is encoded in viral RNA sequence originating at position 56 and terminating at position 1529 from the 5' terminus of the S RNA. A short, noncoding, intergenic region capable of forming a hairpin structure separates the termination codons of the nucleoprotein (N) and GPC genes. Hydropathic analysis of the GPC gene product of Lassa virus indicates the presence of hydrophobic domains near the amino and carboxy termini as previously noted in the corresponding proteins of Pichinde and LCM viruses. A comparison of the nucleotide sequences on the 3' termini of the viral and viral-complimentary S RNA species of Lassa, LCM, and Pichinde viruses reveals slight sequence differences that may possibly be involved in the regulation of RNA synthesis and gene expression.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3750844     DOI: 10.1016/0042-6822(86)90438-1

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  40 in total

1.  NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs.

Authors:  K J Lee; I S Novella; M N Teng; M B Oldstone; J C de La Torre
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Identification of a novel consensus sequence at the cleavage site of the Lassa virus glycoprotein.

Authors:  O Lenz; J ter Meulen; H Feldmann; H D Klenk; W Garten
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P.

Authors:  Winfried R Beyer; Dennis Pöpplau; Wolfgang Garten; Dorothee von Laer; Oliver Lenz
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

4.  Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus.

Authors:  Mar Perez; Juan Carlos de la Torre
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Replicon system for Lassa virus.

Authors:  Meike Hass; Uta Gölnitz; Stefanie Müller; Beate Becker-Ziaja; Stephan Günther
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

6.  Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence.

Authors:  Ana Grande-Pérez; Gema Gómez-Mariano; Pedro R Lowenstein; Esteban Domingo
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  Lassa virus glycoproteins: antigenic and immunogenic properties of synthetic peptides to GP1.

Authors:  A G Krasko; A B Moshnikova; A T Kozhich; L D Tchikin; V T Ivanov; A S Vladyko; I S Lukashevich
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

8.  Host-derived 5' ends and overlapping complementary 3' ends of the two mRNAs transcribed from the ambisense S segment of Uukuniemi virus.

Authors:  J F Simons; R F Pettersson
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

9.  Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates.

Authors:  Igor S Lukashevich; Ricardo Carrion; Maria S Salvato; Keith Mansfield; Kathleen Brasky; Juan Zapata; Cristiana Cairo; Marco Goicochea; Gia E Hoosien; Anysha Ticer; Joseph Bryant; Harry Davis; Rasha Hammamieh; Maria Mayda; Marti Jett; Jean Patterson
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

Review 10.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.